Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

FIBRINOGEN: Prophylactic trials: intervention vs inactive control

Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).

2 findings from 1 review

FXIII: Prophylactic trials: intervention vs inactive control

Arterial thromboembolic events Post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FXIII: Prophylactic trials: intervention showed no clear difference in arterial thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).

1 finding from 1 review

FXIII: Prophylactic trials: intervention vs inactive control

Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs haemostatically active control

All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review

Intervention not reported

Next‐day alertness Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review

Transfusion of RBCs of shorter vs longer storage duration

Mortality: in‐hospital mortality (within 7 days) · all conditions

It is very uncertain whether transfusion of RBCs of shorter changes mortality: in‐hospital mortality (within 7 days) compared with longer storage duration (very low certainty).

1 finding from 1 review

Transfusion of RBCs of shorter vs standard practice storage duration

Mortality: short‐term mortality (up to 30 days) ‐ neonates · all conditions

It is very uncertain whether transfusion of RBCs of shorter changes mortality: short‐term mortality (up to 30 days) ‐ neonates compared with standard practice storage duration (very low certainty).

1 finding from 1 review

Transfusion of RBCs of shorter vs standard practice storage duration

Mortality: short‐term mortality (up to 30 days) ‐ adults · all conditions

Transfusion of RBCs of shorter showed no clear difference in mortality: short‐term mortality (up to 30 days) ‐ adults compared with standard practice storage duration (moderate certainty).

1 finding from 1 review